It’s likely to still be there at the end of the year, but by the time the final sales figures for 2024 are tallied up, Novo ...

Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the ...

The stock's fall snapped a two-day winning streak.

2024 was one of the most eventful years for the pharmaceutical, biotech, life sciences and medical marketing industries.

In this deep dive BioSpace explores the opportunities and challenges presented by the FDA’s accelerated approval program.

Trump touched off a frenzy over RFK Jr. and vaccines — one reporter asked "What about the polio vaccine?" and Trump responded "everything should be looked at." ...

Aussies who feel unwell have been urged to isolate and stay home as a fresh wave of Covid-19 runs rampant on one side of the ...

As of the latest trading close, PFE, a Healthcare sector stock, is trading -18.90% below its 52-week high but remains 4.49% above its 52-week low. The Average True Range (ATR) (14 days) of 0.55 ...

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling ...

Both radiotherapy and endocrine therapy are good single-modality options for women 70 years or older with early, favorable ...